Affimed GmbH
- Country
- 🇩🇪Germany
- Ownership
- Public, Subsidiary
- Established
- 2000-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.affimed.com
Clinical Trials
19
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Phase 2 Study of AFM13 in Combination with AB-101 in Subjects with R/R HL and CD30+ PTCL
- Conditions
- Relapsed or Refractory Hodgkin LymphomaPeripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Affimed GmbH
- Target Recruit Count
- 154
- Registration Number
- NCT05883449
- Locations
- 🇺🇸
UNC Immunotherapy Team, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Affimed GmbH
- Target Recruit Count
- 24
- Registration Number
- NCT05817058
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇫🇷Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse, France
🇫🇷Gustave Roussy, Villejuif Cedex, France
Study to Assess AFM24 in Combination with Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2021-11-05
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Affimed GmbH
- Target Recruit Count
- 148
- Registration Number
- NCT05109442
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Study to Assess AFM24 in Advanced Solid Cancers
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: 480 mg AFM24Drug: 14 mg AFM24Drug: 40 mg AFM24Drug: 160 mg AFM24Drug: 320 mg AFM24Drug: 80 mg AFM24Drug: 720 mg AFM24
- First Posted Date
- 2020-02-06
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Affimed GmbH
- Target Recruit Count
- 85
- Registration Number
- NCT04259450
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Dana Faber Cancer Institute, Boston, Massachusetts, United States
🇩🇪Nordwest Hospital GmbH, Frankfurt am Main, Hessen, Germany
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides
- Conditions
- Peripheral T Cell LymphomaTransformed Mycosis Fungoides
- Interventions
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Affimed GmbH
- Target Recruit Count
- 108
- Registration Number
- NCT04101331
- Locations
- 🇺🇸
University of Alabama at Birmingham (O'Neal Comprehensive Cancer Center), Birmingham, Alabama, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸University of California Los Angeles (UCLA) Health, Los Angeles, California, United States
- Prev
- 1
- 2
- Next